PMID- 18660731
OWN - NLM
STAT- MEDLINE
DCOM- 20081114
LR  - 20151119
IS  - 1530-6550 (Print)
IS  - 1530-6550 (Linking)
VI  - 9
IP  - 2
DP  - 2008 Spring
TI  - Myocardial glucose transport and utilization: a target for therapeutic 
      intervention.
PG  - 106-10
AB  - Patients with type 2 diabetes mellitus (T2DM) have a 2-fold to 4-fold greater 
      risk of cardiovascular mortality than nondiabetic individuals. The overall 
      mortality rate of patients with T2DM is approximately twice that of people 
      without diabetes. The excess in-hospital mortality of these patients is primarily 
      due to an increased risk of congestive heart failure. Reduced compensatory 
      ability of the noninfarcted myocardium and an underlying abnormality in the 
      myocardial substrate metabolism (referable to the diabetic state) may also 
      contribute to poor outcomes. Insulin resistance (IR) is a significant predictor 
      of cardiovascular mortality and morbidity across a spectrum of glucose tolerance. 
      Cardiac mass increases across the range of IR in subjects without diabetes, as 
      well as across the range of glucose intolerance in subjects with diabetes. In one 
      study, elevated fasting plasma glucose was an independent predictor of 
      hospitalization for heart failure. Optimization of cardiac metabolism could 
      become a new target for therapeutic intervention in patients with ischemic heart 
      disease and diabetes.
FAU - Singh, Premranjan P
AU  - Singh PP
AD  - Harvard Medical School, Boston, MA and Lahey Clinic Medical Center, Burlington, 
      Massachusetts, USA.
FAU - Lago, Rodrigo M
AU  - Lago RM
FAU - Nesto, Richard W
AU  - Nesto RW
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Singapore
TA  - Rev Cardiovasc Med
JT  - Reviews in cardiovascular medicine
JID - 100960007
RN  - 0 (Biomarkers)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Biomarkers/metabolism
MH  - Diabetes Mellitus, Type 2/complications/*metabolism/therapy
MH  - Energy Metabolism/drug effects
MH  - Fatty Acids, Nonesterified/therapeutic use
MH  - Glucose/*metabolism
MH  - Glucose Intolerance
MH  - Heart Failure/etiology/*metabolism/mortality/prevention & control
MH  - Humans
MH  - Insulin Resistance
MH  - *Models, Cardiovascular
MH  - Myocardium/*metabolism
MH  - Prognosis
MH  - Survival Analysis
RF  - 22
EDAT- 2008/07/29 09:00
MHDA- 2008/11/15 09:00
CRDT- 2008/07/29 09:00
PHST- 2008/07/29 09:00 [pubmed]
PHST- 2008/11/15 09:00 [medline]
PHST- 2008/07/29 09:00 [entrez]
PST - ppublish
SO  - Rev Cardiovasc Med. 2008 Spring;9(2):106-10.